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OBJECTIVES We studied the clinical features of hypertrophic cardiomyopathy (HCM) caused by a novel
mutation in the myosin binding protein-C (MyBP-C) gene in patients and family members
of Japanese descent.
BACKGROUND Previous reports have demonstrated that the clinical features of HCM associated with
mutations in the MyBP-C gene include late onset and a favorable clinical course. Recently,
some mutations in genes encoding sarcomeric proteins have been reported to be a cause of
dilated cardiomyopathy (DCM), as well as HCM. However, mutations of the MyBP-C gene
have not been reported as a cause of DCM up to now.
METHODS We analyzed MyBP-C gene mutations in 250 unrelated probands with HCM and in 90 with
DCM. We used electrocardiography (ECG) and echocardiography to determine clinical
phenotypes.
RESULTS We identified 17 individuals in 8 families (7 HCM, 1 DCM) with an Arg820Gln mutation
in the MyBP-C gene. Overall, 2 (40%) of 5 carriers age 70 years displayed “burnt-out”
phase HCM, and one of them had been diagnosed as having DCM before genetic
identification. The disease penetrance in subjects age50 years was 70% by echocardiography
and 100% by ECG, and that in those age 50 years was 40% and 50%, respectively.
CONCLUSIONS Elderly patients with Arg820Gln mutation may show “burnt-out” phase HCM, and patients
with this mutation may be included among those diagnosed as having DCM. Screening of
patients with DCM, as well as HCM, for this mutation is of significant importance because
patients with this mutation may be diagnosed clinically as having DCM. (J Am Coll
Cardiol 2003;41:781–6) © 2003 by the American College of Cardiology Foundation
Hypertrophic cardiomyopathy (HCM) is a primary cardiac
disorder, often transmitted genetically, with heterogeneous
clinical and morphologic expression. Recent molecular ge-
netic studies have revealed that HCM is caused by muta-
tions in the genes that encode the sarcomeric proteins (1).
Myosin binding protein-C (MyBP-C) is one of these
sarcomeric proteins, and mutations in the MyBP-C gene on
chromosome 11 are a frequent cause of HCM (2). Several
reports have demonstrated a genotype-phenotype correla-
tion, in that the clinical features of mutations in the
MyBP-C gene include late onset and a favorable clinical
course (2–5). However, it seems that there are some
differences between the various mutations in the MyBP-C
gene in terms of the clinical manifestations of the disease
(6).
On the other hand, the pathogenesis of idiopathic dilated
cardiomyopathy (DCM) is poorly understood. It has been
reported that dystrophin, desmin, tafazzin, and lamin A/C
gene mutations are associated with DCM (7–11). Interest-
ingly, in addition to these findings, mutations of actin,
beta-myosin heavy chain, and the troponin T gene encoding
sarcomeric proteins have been reported to be causes of
DCM as well as HCM (12,13). These reports suggest that
patients with mutations in other genes encoding sarcomeric
proteins may be diagnosed as having DCM. However,
mutation of the MyBP-C gene has not been reported as a
cause of DCM up to now. The purpose of this study was to
screen for MyBP-C gene mutation in the probands and
family members of patients with HCM and DCM, and to
clarify the genotype-phenotype correlation of the disease.
METHODS
Subjects. The study subjects comprised 250 unrelated pro-
bands with HCM (118 familial, 132 sporadic) and 90
unrelated probands with DCM (12 familial, 78 sporadic or
unknown). All probands were identified at the Kanazawa
University Hospital and associated hospitals (from primary
to tertiary care centers). The diagnosis of HCM was based
on the echocardiographic demonstration of a non-dilated,
hypertrophied left ventricle (LV) in the absence of other
cardiac or systemic causes of LV hypertrophy (14). The
diagnosis of DCM was based on the echocardiographic
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demonstration of a dilated LV in the absence of other
cardiac or systemic causes of LV dilation (15). If the
mutation was identified in the probands with HCM or
DCM, their family members were studied genetically and
clinically. Informed consent was obtained from all subjects
or their guardians in accordance with the guidelines of the
Bioethical Committee on Medical Researches, School of
Medicine, Kanazawa University.
Detection of mutation. Deoxyribonucleic acid (DNA) was
isolated from peripheral white blood cells of all subjects
using a DNA extractor 341 Nucleic Acid Purification
System (GENEPURE, PE Biosystems, Foster City, Cali-
fornia). In vitro amplification of genomic DNA was per-
formed using the polymerase chain reaction (PCR). Oligo-
nucleotide primers were used to amplify exons of the
MyBP-C gene as described previously (16). Single-strand
conformational polymorphism (SSCP) analysis of amplified
DNA was then performed using a method described previ-
ously (17). For abnormal SSCP patterns, PCR products
were subcloned into the pCR2.1 vector using the TOPO
TA cloning kit (Invitrogen, Carlsbad, California). The
nucleotide sequences of the cloned PCR products were
determined on both strands by the dye terminator cycle
sequencing method with use of an automated fluorescent
sequencer (ABI PRISM 310 Genetic Analyzer, PE Biosys-
tems). The sequence variation in the MyBP-C gene was
confirmed by restriction enzyme digestion. The presence of
an Arg820Gln missense mutation, which creates a Pvu II
restriction site, was confirmed by digestion of genomic
DNA with this enzyme. The same method was then used to
determine the genotype in DNA from family members of
the probands and in 100 healthy individuals.
Clinical evaluations. Evaluation of the phenotype was
completed before determination of the genotype. All sub-
jects underwent echocardiography and/or 12-lead electro-
cardiography (ECG). Disease penetrance was determined
by the following criteria: 1) LV end-diastolic maximal wall
thickness 13 mm; 2) LV end-diastolic dimension 55
mm and fractional shortening25%; 3) Q-wave0.04 s in
duration or one-fourth of the ensuing R-wave in depth in at
least two leads; 4) significant ST-T changes; 5) left ventric-
ular hypertrophy (Romhilt-Estes score 4); and 6) conduc-
tion disturbance. Family members were evaluated similarly.
RESULTS
Genetic results. The 250 probands with HCM comprised
190 men and 60 women, and the 90 probands with DCM
comprised 65 men and 25 women. An Arg820Gln missense
mutation in the MyBP-C gene was identified in 8 probands
(7 in HCM, 1 in DCM) (Fig. 1). Although we screened for
all MyBP-C exons in carriers with the Arg820Gln missense
mutation, no other sequence variants were identified in the
MyBP-C gene. Relatives of these eight probands were
studied further, totaling 24 members of the various families
(Fig. 2). Of these 24 individuals, 17 (9 men and 8 women,
mean age 55.1  20.0 years) had the Arg820Gln missense
mutation in the cardiac MyBP-C gene. This mutation was
not observed in any of 100 unrelated healthy individuals.
Clinical manifestations. All 17 carriers in the eight fam-
ilies were evaluated by ECG studies. Fifteen of these 17
carriers were examined by echocardiography, but agreement
was not obtained from the other two. The echocardio-
graphic results are shown in Table 1. Asymmetrical septal
hypertrophy was found in seven subjects (47%). The mean
maximal LV wall thickness was 15.1  5.9 mm. “Burnt-
out” phase HCM (fractional shortening 25%, and LV
end-diastolic dimension 55 mm) was observed in two
(40%) of five carriers age 70 years, and one of them had
been diagnosed as having primary DCM before genetic
identification (DCM-006). Echocardiographic abnormali-
ties were noted in 9 of 15 carriers. The ECG results are
shown in Table 2. Fifteen of 17 carriers had sinus rhythm.
The other carriers had chronic atrial fibrillation, and one of
them had been implanted with a pacemaker. Abnormal Q
waves were noted in two subjects and significant ST-T
changes in 15 subjects. The disease penetrance in subjects
age 50 years was 70% by echocardiography and 100% by
ECG, and in those age 50 years was 40% and 50%,
respectively. Sudden death occurred in two subjects from
one family (HCM-089, I-1, II-1).
Abbreviations and Acronyms
DCM  dilated cardiomyopathy
DNA  deoxyribonucleic acid
ECG  electrocardiography
HCM  hypertrophic cardiomyopathy
LV  left ventricle
MyBP-C  myosin binding protein-C
PCR  polymerase chain reaction
SSCP  single-strand conformational polymorphism
Figure 1. A single base pair sequence variant on one allele (guanine to
adenosine, second position) encodes a mutant myosin binding protein-C
that contains glutamine at residue 820.
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Figure 2. Pedigrees of HCM-011, HCM-023, HCM-084, HCM-089, HCM-168, HCM-171, and DCM-006. The genotypic and phenotypic status of
subjects is indicated in the key. DCM  dilated cardiomyopathy; HCM  hypertrophic cardiomyopathy.
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DISCUSSION
In this study, we demonstrated that elderly patients with the
Arg820Gln mutation in the MyBP-C gene may show
“burnt-out” phase HCM, and that patients with this mu-
tation may be included among those diagnosed as having
DCM.
Arg820Gln mutation in the MyBP-C gene and its con-
sequences. We identified the Arg820Gln missense muta-
tion in exon 25 of the MyBP-C gene. This sequence variant
was found in clinically affected patients and was absent in
100 normal controls. We screened for all MyBP-C exons in
carriers with the Arg820Gln missense mutation, and there
were no other sequence variants in the MyBP-C gene.
These findings suggest that the Arg820Gln missense mu-
tation in the MyBP-C gene may be associated with disease.
This mutation occurs in motif VI (fibronectin type III
repeat) (16). Arg820 is conserved in human, chicken, and
mouse cardiac isoforms (Table 3). A missense mutation in a
conserved position of the MyBP-C gene suggests a mech-
anism by which the function of the protein may be altered.
However, Arg820 is not included in the region that is
essential for A-band incorporation, titin-binding, or
myosin-binding (6). Moreover, missense mutations in the
MyBP-C gene cause a more mild disease phenotype than
Table 1. Echocardiographic Findings in the Carriers With Arg820Gln in the MyBP-C Gene
Family Member Gender
Age
(yrs)
IVST
(mm)
PWT
(mm)
IVST
LVDd
(mm)
LVDs
(mm)
FS
(%) ASH SAMPWT
HCM-011 II-1 F 76 14 11 1.3 36 22 39 Yes No
II-4 M 71 16 10 1.6 58 45 22 Yes No
III-4 F 42 ND ND ND ND ND ND ND ND
III-5 F 36 10 9 1.1 44 29 34 No No
III-6 F 34 10 9 1.1 42 24 41 No No
IV-3 M 16 19 10 1.9 42 25 40 Yes Yes
HCM-023 II-1 M 55 25 14 1.8 38 22 42 Yes No
HCM-084 II-6 F 75 10 10 1.0 50 30 40 No No
HCM-089 II-3 F 77 ND ND ND ND ND ND ND ND
II-12 M 69 11 10 1.1 43 24 44 No No
II-13 F 68 12 10 1.2 40 26 35 No No
II-14 M 64 21 12 1.8 47 26 45 Yes No
HCM-168 II-2 M 44 28 14 2.0 47 27 42 Yes Yes
III-2 M 18 9 9 1.0 44 28 36 No No
HCM-171 II-2 F 54 16 12 1.3 42 25 40 Yes No
HCM-213 II-1 M 72 16 9 1.8 45 33 33 Yes No
DCM-006 II-2 M 71 10 10 1.0 56 48 14 No No
Yes  presence of a finding; No  absence of a finding.
ASH  asymmetrical septal hypertrophy; FS  fractional shortening; IVST  interventricular septal wall thickness; LVDd  left ventricular end-diastolic dimension;
LVDs left ventricular end-systolic dimension; MyBP-Cmyosin binding protein-C; ND not determined; PWT left ventricular posterior wall thickness; SAM systolic
anterior movement.
Table 2. Electrocardiographic Findings in the Carriers With Arg820Gln in the MyBP-C Gene
Family Member
Age
(yrs) Rhythm
Abnormal
Q-Wave
SV1RV5/6
(mV)
ST-T
Change
HCM-011 II-1 76 SR No 3.3 Yes
II-4 71 Af, PM No 5.4 Yes
III-4 42 SR No 2.5 No
III-5 36 SR No 3.5 No
III-6 34 SR No 1.5 No
IV-3 16 SR Yes 3.7 Yes
HCM-023 II-1 55 SR No 3.5 Yes
HCM-084 II-6 75 SR No 7.7 Yes
HCM-089 II-3 77 SR No 5.8 Yes
II-12 69 SR Yes 2.7 Yes
II-13 68 SR No 2.4 Yes
II-14 64 SR No 5.0 Yes
HCM-168 II-2 44 SR No 4.6 Yes
III-2 18 SR No 3.5 Yes
HCM-171 II-2 54 SR No 4.6 Yes
HCM-213 II-1 72 SR No 2.8 Yes
DCM-006 II-2 71 SR No 2.8 Yes
Yes  presence of a finding; No  absence of a finding.
Af  atrial fibrillation; MyBP-C  myosin binding protein-C; PM  pacemaker; RV5/6  amplitude of R-wave in lead
V5 or V6; SR  sinus rhythm; SV1  amplitude of R-wave in lead V1.
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truncation mutations (6). For these reasons, carriers with
the Arg820Gln mutation in the MyBP-C gene may not
show a severe disease phenotype until middle age. On the
other hand, this mutation resulted in a change of the charge
of the altered amino acid. Anan et al. (18) suggested that
patients with mutations that changed the charge of the
altered amino acid in the beta-myosin heavy chain gene
displayed a malignant phenotype. Concerning the MyBP-C
gene, four mutations have been reported (Glu258Lys,
Arg654His, Val896Met, Val1115Ile) which do not change
the charge of the amino acid residue (2,6,19,20). The
clinical features of carriers with two (Arg654His,
Val1115Ile) of these four mutations have been described in
previous reports, although extended family studies were not
performed. There were no individuals with these mutations
who showed “burnt-out” phase HCM. In our study, we
observed LV dilation and dysfunction in elderly individuals.
This unfavorable course in the elderly may relate to the
mutation that changed the charge of the altered amino acid.
Disease penetrance and sudden death. Niimura et al. (2)
have reported that the cardiac MyBP-C mutation is char-
acterized by low disease penetrance in HCM. We observed
that the disease penetrance in subjects age 50 years was
70% by echocardiography and 100% by ECG, and in those
age 50 years was 40% and 50%, respectively. Our data are
similar to four recent reports (2–5).
Onset of the disease associated with this mutation ap-
pears to be late. However, a 16-year-old youth (family
HCM-011, IV-3) showed features typical of HCM. This
finding indicates that we should also evaluate young family
members of patients, because they already may be affected
clinically.
It is reported that sudden death occurs rarely in family
members with mutations in the MyBP-C gene (4). In this
study, sudden death occurred in two subjects only in one
(HCM-089) of these eight families. A middle-aged subject
(HCM-089, I-1) died suddenly after exercise, and an elderly
subject (HCM-089, II-1) died suddenly after dinner. These
findings suggest that some modifying genes may be associ-
ated with sudden death occurring in members of this family.
Further investigations are needed to clarify the modifying
genes. Moreover, Niimura et al. (2) reported that some
missense mutations in the MyBP-C gene showed a higher
association with sudden death during exercise. Sudden
death may occur in family members with mutations in the
MyBP-C gene, including the Arg820Gln missense muta-
tion.
Clinical manifestations. Elderly carriers with the
Arg820Gln missense mutation may show LV systolic dys-
function and dilation. We observed “burnt-out” phase
HCM in two (40%) of five elderly carriers, and one of them
had been diagnosed as having primary DCM before genetic
identification (DCM-006). Previous reports suggested that
a small fraction (10%) of patients with HCM progress
gradually to a “burnt-out” phase later in their lives (21,22).
In medical practice, “burnt-out” phase HCM is not rare in
elderly patients with this mutation. There are few previous
reports that mention LV systolic dysfunction in patients
with HCM associated with the MyBP-C gene. Moolman et
al. (4) recently reported the clinical expression of HCM
associated with a single base insertion in exon 25 of the
MyBP-C gene. Their report did not include individuals
with LV dysfunction and dilation. In contrast, Doi et al.
(23) reported that four individuals with a one base deletion
in codon 593 from TCC (Ser) to CC in exon 18 of the
cardiac MyBP-C gene gradually progressed to the stage of
LV dilation and dysfunction later in their lives. However,
the percentage of the patients who progressed to LV
dilation and dysfunction was not given in this report. We
performed cardiac catheterization and myocardial biopsy for
the proband of family DCM-006, who was diagnosed
clinically as having DCM with the Arg820Gln missense
mutation. Coronary arteriography showed no significant
stenosis. Left ventriculography showed diffuse severe hypo-
kinesis of the LV wall, and the LV ejection fraction was
15%. Myocardial biopsy revealed mild fibrosis, no myocar-
dial hypertrophy, and no myofibrillar disarray. These find-
ings suggest that it is difficult to differentiate clinically the
“burnt-out” phase HCM from DCM. Indeed, he had been
diagnosed clinically as having idiopathic DCM before
genetic identification. We should screen patients diagnosed
as having DCM for sarcomeric protein genes, including the
cardiac MyBP-C gene. Some mutations in the beta-myosin
heavy chain and the troponin T gene also have been
reported to cause HCM with LV dysfunction (24–27).
Kokado et al. (28) reported that a Lys183 deletion mutation
in the troponin I gene in patients with HCM is associated
with LV systolic dysfunction and dilation in those age 40
years. Similar to the Lys183 deletion mutation in the cardiac
troponin I gene, the Arg820Gln missense mutation in the
MyBP-C gene may be one of the genetic factors of
“burnt-out” phase HCM in elderly patients. This is the first
report that indicates a relationship between mutation and
LV systolic dysfunction in the MyBP-C gene in patients
Table 3. Conservation of Arginine 820 in Cardiac MyBP-C
820
Human cMyBP-C 4K K K S Y R W M R L N F D L I Q E3
Chicken cMyBP-C K K K S Y R W M R L N F D L L K E
Mouse cMyBP-C K K K S Y R W M R L N F D L L R E
Human fast sMyBP-C K K G S Q R W M K L N F E V F T E
Chicken fast sMyBP-C K K G S M R W M K L N F E V F P D
cMyBP-C  cardiac myosin binding protein-C; sMyBP-C  skeletal myosin binding protein-C.
785JACC Vol. 41, No. 5, 2003 Konno et al.
March 5, 2003:781–6 HCM Associated With a Novel MyBP-C Mutation
with HCM. Furthermore, this is the first report that
indicates that patients with “burnt-out” phase HCM caused
by MyBP-C mutation may be included among those diag-
nosed as having DCM. We need to screen for the
Arg820Gln missense mutation in patients with DCM, as
well as those with HCM, because patients with this muta-
tion may be diagnosed clinically as having DCM.
Conclusions. The Arg820Gln missense mutation in the
MyBP-C gene is associated with variable clinical features,
and the clinical expression of this mutation is often delayed
until middle age. Elderly patients with this mutation may
show “burnt-out” phase HCM and may be included among
those diagnosed as having DCM. We conclude that screen-
ing for this mutation in patients, especially those who are
elderly, with DCM, as well as those with HCM, is of
significant importance because patients with this mutation
may be diagnosed clinically as having idiopathic DCM.
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